8-K: Kintara Therapeutics Announces Q2 Fiscal 2024 Results and Strategic Review

Kintara Therapeutics reported its second quarter fiscal 2024 results, highlighted by a reduced net loss and the initiation of a new clinical trial for its REM-001 therapy, while also announcing a strategic review process.

Summary

• Kintara Therapeutics announced its financial results for the second fiscal quarter ended December 31, 2023, and provided a corporate update.
• The company initiated a 15-patient study for REM-001 in cutaneous metastatic breast cancer (CMBC), with the majority of costs covered by a $2.0 million NIH grant.
• Kintara's Board of Directors has begun exploring strategic alternatives to maximize stockholder value, engaging Ladenburg Thalmann & Co. Inc. as a financial advisor.
• The company terminated the development of VAL-083 after preliminary results from the GBM AGILE study showed it did not outperform current standards of care.
• Kintara had approximately $0.7 million in cash and cash equivalents as of December 31, 2023.
• From January 1, 2024, to February 12, 2024, the company received net proceeds of approximately $6.1 million from the sale of common stock, primarily through its ATM facility.
• The net loss for the three months ended December 31, 2023, was approximately $1.0 million, or $0.24 per share, compared to a net loss of approximately $3.5 million, or $2.10 per share, for the same period in 2022.
• The decreased net loss was primarily due to lower research and development expenses and reduced general and administrative costs.
• The company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC), which has shown 80% complete responses in evaluable lesions in previous studies.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the termination of the VAL-083 program and the low cash position, despite the positive developments with REM-001 and cost-cutting measures. The strategic review also introduces uncertainty.

Positives

• The company has initiated a new clinical trial for REM-001 in CMBC, a disease with limited treatment options.
• Kintara secured a $2.0 million grant from the NIH to cover the majority of the costs for the REM-001 study.
• The company's net loss decreased significantly year-over-year, primarily due to lower research and development expenses and reduced general and administrative costs.
• Kintara has strengthened its balance sheet with net proceeds of approximately $6.1 million from the sale of common stock.
• REM-001 has shown promising clinical efficacy with 80% complete responses in previous studies of CMBC.

Negatives

• Kintara terminated the development of VAL-083 after it failed to outperform current standards of care in the GBM AGILE study.
• The company had approximately $0.7 million in cash and cash equivalents as of December 31, 2023.
• Kintara reported a net loss of approximately $1.0 million for the three months ended December 31, 2023.
• The company's working capital is in a deficiency of $684,000 as of December 31, 2023.

Risks

• The company's ability to develop, market, and sell products based on its technology is subject to risks and uncertainties.
• The status of the company's clinical trials and the expected benefits and efficacy of its products are uncertain.
• The company's ability to secure additional funding to continue operations and conduct research and development is a risk.
• Global unrest could impact the company's business, research, and development plans.
• The strategic review process may not result in a transaction that maximizes shareholder value.

Future Outlook

The company is focused on the development of REM-001 and is evaluating strategic options to maximize shareholder value. The company is also seeking additional funding to continue operations and conduct research and development.

Management Comments

• We are pleased to have recently initiated our 15 patient REM-001 study for cutaneous metastatic breast cancer, a disease with little or no current treatment options, commented Robert E. Hoffman, Kintara's President and Chief Executive Officer.
• We have strengthened our balance sheet primarily with net proceeds from our at-the-market (ATM) facility and aggressive cost-cutting efforts.
• We continue to evaluate strategic options with the goal of maximizing shareholder value.

Industry Context

The announcement reflects the challenges and risks inherent in the biopharmaceutical industry, particularly in oncology drug development. The termination of VAL-083 highlights the high failure rate of clinical trials, while the focus on REM-001 and the strategic review indicate a pivot towards more promising assets and potential value creation opportunities. The company is operating in a competitive landscape where companies are constantly seeking to develop novel therapies for unmet medical needs.

Comparison to Industry Standards

• The termination of VAL-083 after failing to outperform standard of care in the GBM AGILE study is not uncommon in the pharmaceutical industry, where many clinical trials fail to meet their endpoints. For example, companies like Novocure have had success with their Optune device for glioblastoma, while others have faced setbacks.
• The focus on REM-001 for CMBC aligns with the industry trend of developing targeted therapies for specific cancer subtypes. Companies like Immunomedics (now part of Gilead) have seen success with antibody-drug conjugates in breast cancer, demonstrating the potential of targeted approaches.
• The strategic review process is a common practice for companies facing financial challenges or seeking to maximize shareholder value. Similar processes have been undertaken by companies like Agenus and Celldex, often leading to mergers, acquisitions, or asset sales.
• The company's cash position of $0.7 million is relatively low compared to other publicly traded biopharmaceutical companies, which often have tens or hundreds of millions in cash reserves. This highlights the need for Kintara to secure additional funding to continue operations.

Stakeholder Impact

• Shareholders face uncertainty due to the strategic review process and the termination of the VAL-083 program.
• Employees may be affected by the cost-cutting measures and the strategic review.
• Patients with CMBC may benefit from the development of REM-001.
• Creditors may be concerned about the company's low cash position.

Next Steps

• Continue the 15-patient REM-001 study in cutaneous metastatic breast cancer (CMBC).
• Evaluate strategic options to maximize shareholder value.
• Seek additional funding to support operations and research and development.

Key Dates

Keywords

Kintara Therapeutics, REM-001, Cutaneous Metastatic Breast Cancer, CMBC, Photodynamic Therapy, PDT, VAL-083, Glioblastoma, GBM AGILE, Clinical Trial, Strategic Alternatives, Financial Results, Biopharmaceutical